Zoetis (ZTS) Income towards Parent Company (2012 - 2026)
Zoetis' (ZTS) quarterly Income towards Parent Company came in at $601.0 million in Q1 2026, little changed year-on-year from $602.0 million in Q1 2025, and little changed on a QoQ basis from $603.0 million in Q4 2025.
Zoetis (ZTS) Income towards Parent Company (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Income towards Parent Company data on file, last reported at $601.0 million in Q1 2026.
- On a quarterly basis, Income towards Parent Company changed 0.17% year-over-year to $601.0 million in Q1 2026; TTM through Mar 2026 was $2.6 billion, a 5.76% increase from a year earlier, with the FY2025 full-year figure at $2.7 billion, up 7.09% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $601.0 million, roughly flat from $603.0 million in the prior quarter.
- Over the last five years, Income towards Parent Company for ZTS reached as high as $721.0 million in Q3 2025 and fell as low as $460.0 million in Q4 2022.
- Historically, Income towards Parent Company has averaged $599.5 million across 5 years, with a median of $599.0 million in 2024.
- On a YoY basis, Income towards Parent Company climbed as much as 26.65% in 2023 and fell as far as 7.24% in 2023.
- Year by year, Income towards Parent Company stood at $460.0 million in 2022, then grew by 13.7% to $523.0 million in 2023, then gained by 11.09% to $581.0 million in 2024, then grew by 3.79% to $603.0 million in 2025, then retreated by 0.33% to $601.0 million in 2026.
- Per Business Quant data, the three most recent Income towards Parent Company figures were $601.0 million in Q1 2026, $603.0 million in Q4 2025, and $721.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 601.00 Mn |
| Dec 31, 2025 | 603.00 Mn |
| Sep 30, 2025 | 721.00 Mn |
| Jun 30, 2025 | 718.00 Mn |
| Mar 31, 2025 | 602.00 Mn |
| Dec 31, 2024 | 581.00 Mn |
| Sep 30, 2024 | 692.00 Mn |
| Jun 30, 2024 | 624.00 Mn |
| Mar 31, 2024 | 599.00 Mn |
| Dec 31, 2023 | 523.00 Mn |
| Sep 30, 2023 | 596.00 Mn |
| Jun 30, 2023 | 670.00 Mn |
| Mar 31, 2023 | 551.00 Mn |
| Dec 31, 2022 | 460.00 Mn |
| Sep 30, 2022 | 528.00 Mn |
| Jun 30, 2022 | 529.00 Mn |
| Mar 31, 2022 | 594.00 Mn |
| Dec 31, 2021 | 413.00 Mn |
| Sep 30, 2021 | 552.00 Mn |
| Jun 30, 2021 | 511.00 Mn |